The FDA has approved use of GlaxoSmithKline’s Boostrix (Tdap) vaccine for use during the third trimester of pregnancy, for prevention of pertussis (whooping cough) in infants younger than two ...

Dynavax is giving up work on its combination vaccine for tetanus, diphtheria and acellular pertussis (Tdap) after mulling phase 1 data for the shot. | Dynavax is giving up on its combination vaccine ...

Likewise, GlaxoSmithKline has taken steps to differentiate Boostrix and Infanrix to help ensure that they are administered properly. Similar to Sanofi Pasteur, they also label pre-filled syringes ...

Canada Persons aged 11–64 Single-dose booster Boostrix GlaxoSmithKline Biologicals, Rixensart, Belgium Persons aged 10–64 Single-dose booster *Persons previously vaccinated who are at ...

GlaxoSmithKline Pharmaceuticals Limited is ... Tetanus and acellular Pertussis (DTP) vaccines, such as Boostrix and Infanrix. Also the company in well positioned to launch the breast cancer ...

Adacel and Boostrix should not be used in ... Sanofi Pasteur. Package insert - Adacel. GlaxoSmithKline. Package insert - Boosterix. Centers for Disease Control and Prevention. Diphtheria, tetanus, and ...

Boostrix can cause certain side effects, some of which are more common than others. These side effects may be temporary, lasting a few days to weeks. However, if the side effects last longer than ...

GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), following a string of exits by companies including Pfizer, UCB, WuXi AppTec and ...

THE ARM FOR THE LANCASTER COUNTY ECONOMY. THIS IS FOR GSK, THE LARGEST INVESTMENT IN MANUFACTURING WE’VE EVER DONE IN THE UNITED STATES. THE $800 MILLION WILL BE USED TO EXPAND GSK’S MARIETTA ...

After making a splash in the U.K. earlier this year, GSK is laying out plans for its biggest U.S. manufacturing investment yet. GSK is investing up to $800 million to double the size and capacity ...

This time, we have GSK (GSK) "GSK" filing a lawsuit against Moderna (NASDAQ:MRNA) accusing them of patent infringement on their lipid nanoparticle (LNP) technology, which is used in mRNA therapeutics.